<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413541</url>
  </required_header>
  <id_info>
    <org_study_id>IRB.575/56</org_study_id>
    <nct_id>NCT02413541</nct_id>
  </id_info>
  <brief_title>The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <brief_summary>
    <textblock>
      This research project is a study to immunology changes in critically ill patients with severe&#xD;
      sepsis by using Endotoxin Activity Assay (EAA) combined with Polymyxin-B Hemoperfusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functions of cell surface markers</measure>
    <time_frame>3 days</time_frame>
    <description>CD11b expression on PMN and HLA-DR expression on monocyte</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotaxis</measure>
    <time_frame>3 days</time_frame>
    <description>Neutrophil function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EAA level</measure>
    <time_frame>3 days</time_frame>
    <description>Endotoxin level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA Score)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury and Renal Replacement Therapy incidences</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation free day</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>High EAA and use Polymyxin-B Hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EAA level &gt; 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High EAA and not use Polymyxin-B Hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EAA level &gt; 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low EAA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EAA level &lt; 0.6 and not use Polymyxin-B Hemoperfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Polymyxin-B Hemoperfusion</intervention_name>
    <description>Endotoxin removal</description>
    <arm_group_label>High EAA and use Polymyxin-B Hemoperfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <arm_group_label>High EAA and not use Polymyxin-B Hemoperfusion</arm_group_label>
    <arm_group_label>Low EAA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SIRS Criteria &gt; or = 2 meets definition&#xD;
&#xD;
          -  Source of infection &gt; or = 1 meet definition&#xD;
&#xD;
          -  Evidence of organ dysfunction &gt; or = 1 meet definition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WBC &lt; 5,000 /ul&#xD;
&#xD;
          -  Platelet &lt; 30,000 / ul&#xD;
&#xD;
          -  Pregnancy woman&#xD;
&#xD;
          -  Advance stage cancer patients (terminally ill) who is refuse to be resuscitated&#xD;
&#xD;
          -  Received blood transfusion &gt; 5 units in 24 hrs&#xD;
&#xD;
          -  Allergy to Polymyxin-B&#xD;
&#xD;
          -  High risk and uncontrolled bleeding&#xD;
&#xD;
          -  Organ transplant patients&#xD;
&#xD;
          -  On immunosuppressive agents within 2 weeks before study&#xD;
&#xD;
          -  HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sasipha Tachaboon</name>
      <address>
        <city>Bangkok</city>
        <state>Pathumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattachai Srisawat ,M.D.</investigator_full_name>
    <investigator_title>Division of Nephrology, Department of Medicine, Faculty of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

